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Abstract
Brain accumulation of the amyloid-b peptide (Ab) and oxidative stress underlie neuronal dysfunction and memory loss in
Alzheimer’s disease (AD). Hexokinase (HK), a key glycolytic enzyme, plays important pro-survival roles, reducing
mitochondrial reactive oxygen species (ROS) generation and preventing apoptosis in neurons and other cell types. Brain
isozyme HKI is mainly associated with mitochondria and HK release from mitochondria causes a significant decrease in
enzyme activity and triggers oxidative damage. We here investigated the relationship between Ab-induced oxidative stress
and HK activity. We found that Ab triggered HKI detachment from mitochondria decreasing HKI activity in cortical neurons.
Ab oligomers further impair energy metabolism by decreasing neuronal ATP levels. Ab-induced HKI cellular redistribution
was accompanied by excessive ROS generation and neuronal death. 2-deoxyglucose blocked Ab-induced oxidative stress
and neuronal death. Results suggest that Ab-induced cellular redistribution and inactivation of neuronal HKI play important
roles in oxidative stress and neurodegeneration in AD.
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Introduction
Hexokinase (HK) catalyzes the first step of glycolysis, i.e., the
ATP-dependent phosphorylation of glucose to glucose-6P (G6P),
with concomitant generation of ADP. Although HK is generally
known as a key glycolytic enzyme, in neurons and other cell types
HK activity also regulates vital cellular processes, including ATP
synthesis and apoptosis [1–3].
In the brain, HKI is the major isozyme present [4], being
mainly (,70–90%) associated with the outer mitochondrial
membrane. Release of HK from mitochondria is known to cause
a severe decrease in enzyme activity [5,6]. Interestingly,
mitochondrial-bound hexokinase I (m-HKI) activity in neurons
has been shown to be neuroprotective, maintaining adequate
glutathione levels, inducing neurite outgrowth, and preventing
neuronal oxidative damage [6–8]. The activity and specific
subcellular localization of neuronal m-HKI is of great significance
to protect neurons from different insults.
We have previously demonstrated that neuronal m-HKI reduces
hyperglycemia-induced generation of excessive ROS through an
ADP recycling mechanism [8]. In the mitochondrial membrane,
HKI is bound to the voltage-dependent anion channel (VDAC),
which is associated with the ADP/ATP carrier. HKI benefits from
preferential access to ATP produced in the mitochondria, while local
ADP generation by HKI facilitates the exchange of ADP and ATP
through the inner mitochondrial membrane [8,9]. This enhances
mitochondrial oxidative phosphorylation and reduces monoelectro-
nic oxygen reduction that gives rise to excessive ROS generation.
Thus, m-HK1 may play an important antioxidant role in the brain.
Several cellular features of the brain suggest that it is highly
sensitive to oxidative stress [10]. Abnormally elevated ROS levels
have been implicated in the age-related impairment of long-term
potentiation (LTP), a well-known model for synaptic plasticity and
learning [11]. It is known that excessive ROS levels are implicated
in the molecular etiology of Alzheimer’s disease (AD) [12–14].
Elevated ROS levels can be selectively dysfunctional in AD, a
disease characterized by memory loss.
Previous investigations have shown that different aggregated
forms of the amyloid-b peptide (Ab) stimulate ROS production in
neurons [14,15]. Accumulation of Ab in AD brains is thought to
underlie neuronal dysfunction and memory loss, being centrally
implicated in AD pathogenesis [16]. In particular, soluble protein
oligomers are currently thought to be emerging toxins in
Alzheimer’s [17–19] and other amyloid diseases [18,20].
We now report that Ab triggers neuronal oxidative stress by
interfering with m-HKI activity and subcellular localization. Exposure
of mature cortical neurons to Ab caused a decrease in m-HKI activity
and its detachment from mitochondria. Ab oligomers further induced
mitochondrial dysfunction and caused a marked reduction in
neuronal ATP levels, indicating an impairment of energy metabolism.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15230By causing a cellular redistribution of HKI, Ab instigates an abnormal
increase in mitochondrial ROS generation that is prevented by 2-
deoxyglucose (2-DOG). Results establish a novel cellular mechanism
underlying oxidative stress and neurodegeneration in AD.
Methods
Materials
Ab1-42 and Ab1-40 were purchased from Bachem (Torrance, CA).
ADP, ATP, horseradish peroxidase, carbonyl cyanide p-trifluor-
omethoxyphenylhydrazone (FCCP), 2-deoxyglucose (2-DOG),
Leuconostoc Mesenteroid’s glucose-6 phosphate dehydrogenase
(G6PDH), Percoll, b-NAD+, bovine serum albumin and poly-L-
lysine were from Sigma-Aldrich (St. Louis, MO). Neurobasal
medium, B27 supplement, Live/Dead cell viability assay kit and
CM-H2DCFDA were from Invitrogen Molecular Probes (Eugene,
OR). Goat polyclonal anti-cytochrome c oxidase and monoclonal
anti-hexokinase-1 antibodies were from Santa Cruz Biotechnology
(SantaCruz,CA).Anti-cyclophilinB rabbitpolyclonalantibody was
from Affinity Bio Reagents (Golden, CO). SuperSignal West Femto
Maximum Sensitivity substrate was from Pierce (Rockford, IL). All
other reagents were of the highest analytical grade available.
Ab preparation
Ab1-42 was freshly dissolved from the lyophilized powder in a
50% (v/v) solution of trifluoroethanol (TFE) in phosphate-buffered
saline (PBS), as described [21–23]. Amyloid aggregation was
triggered by dilution of small aliquots from this stock solution into
PBS (resulting in # 0.5% residual TFE) to yield final
concentrations of 5 mMo r2 0mMA b.
Alternatively, Ab oligomers were prepared as previously described
[14,24,25]. Briefly, the peptide was dissolved to 1 mM in hexafluoro-
2-propanol and stored in aliquots as a dried film at 280uCa f t e r
solvent evaporation. The film was resuspended in DMSO to a final
concentration of 5 mM. The solution was diluted to 100 mM in ice-
coldPBSandleftat4uC overnight. The solution was then centrifuged
at 14,0006gf o r1 0m i na t4 uC and the supernatant was collected,
transferred to a clean tube and stored at 4uC for a maximum of
24 hours until use. Ab1-40 monomer solution was prepared in aliquots
as a dried hexafluoro-2-propanol film and stored at -80uC. The
peptide film was dissolved in undiluted, sterile DMSO to make a
5 mM solution. The solutionwas diluted to 100 mMw it hH a m’ sF - 1 2
medium without glutamine and immediately centrifuged (14,0006g/
10 min/4uC) to remove insoluble aggregates. The supernatant was
transferred to a clean tube and used immediately.
Brain mitochondrial isolation, determination of HK
activity and isolation of neuronal cytosolic and
mitochondria fractions
Mitochondria were isolated from forebrains by conventional
differential centrifugation as previously described [8]. m-HKI
activity was determined using an enzymatic assay coupled to
Leuconostoc Mesenteroid’s G6PDH activity, monitoring hexokinase
activity indirectly by NADH formation at l=340 nm [8].
Cytosolic and mitochondria-enriched fractions from primary
cultures of rat cortical neurons were isolated as described [8].
Neuronal cultures and reactive oxygen species (ROS)
formation
Cortices from 14-day-old rat embryos were dissected and
cultured as previously described [22,26] with minor modifications.
Cells were plated on glass coverslips previously coated with 1.5 mg/
ml poly-L-lysine in Neurobasal medium supplemented with B27
and cultures were maintained at 37uC in a humidified 5% CO2
atmosphere for 14–18 days prior to use. ROS formation was
evaluated in live cortical neurons using 2 mMC M - H 2DCFDA [14].
Probe fluorescence was analyzed using NIH Image J software [27]
as described [14]. 16 images were analyzed in each experimental
condition(carriedout intriplicatewellsineachofthreeindependent
experiments using different neuronal cultures) and were combined
to allow quantitative estimates of changes in ROS levels.
Neuronal viability and MTT assays
Ab1-42 (20 mM), in the absence or in the presence of 30 mM 2-
DOG, was added to cultures and was kept in the medium for
48 hours. Control cultures consisting of neurons cultured in
growth medium alone or in the presence of residual TFE (0.5% v/
v) were also prepared. Cell viabilities in cultures were assessed
using the Live/Dead kit. Live neurons were identified by green
calcein fluorescence and dead neurons were identified by red
propidium iodide fluorescence. Percentages of live neurons are
expressed relative to the total number of neurons in each field.
Five randomly chosen fields independent fields were imaged on a
Nikon Eclipse TE300 microscope and analyzed in different
experimental conditions (carried out in at least triplicate wells in
each of three independent experiments using different cultures).
MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazolium
bromide) assay (Boehringer Mannheim, Indianapolis, IN) was
used to evaluate the cellular metabolic redox activity. Nineteen-
day old hippocampal neuronal cultures were used. Three
independent experiments (each with 6 wells per experimental
condition) were carried out with different neuronal cultures.
Measurement of intracellular ATP levels
ATP contents in 19-day old rat cortical neurons were analyzed
by ion-paired reverse phase liquid chromatography. Cultures were
exposed to 500 nM ADDLs or vehicle for 12 hours. Medium was
then removed and cells were washed twice with cold PBS. Liquid
nitrogen was used to disrupt cells and stop cellular metabolism.
The plates were kept in an ice bath until the liquid nitrogen
evaporated completely. Cells were then homogenized with 6%
trichloroacetic acid, neutralized by adding a small aliquot of a 1M
Tris solution, and centrifuged at 20,8006g for 5 min at 4uC.
Protein contents were determined using the BCA method.
Aliquots were injected into an HPLC system using a Supelguard
column (Supelco) coupled to a Supercosil C-18 carrier (particle
size of 5 mm, Supelco) column. Isocratic elution was performed at
a flow-rate of 1 mL/min at room temperature with 50 mM
KH2PO
4 buffer, pH 6.0/methanol (90/10) and 4 mM tetrabutyl
ammonium bromide. ATP levels were measured by UV
absorbance at 254 nm. ATP peaks were identified by co-injecting
2 nmols of ATP in an independent run. Results were expressed by
normalizing peak areas by the total amount of protein obtained.
Determination of intracellular glucose-6P content
Ab1-42 (5 mM), in the the presence of 30 mM 2-DOG, was added
to cultures after 7 days in vitro and was kept in the medium for
24 hours. Cells were scraped in 200 mL of 6% (v/v) trichloroacetic
acid per plate (35 mm2 dishes). The extract was neutralized by
adding 80 mL of 1.0 M Tris solution. G6P levels were determined
using an enzymatic assay coupled to G6PDH activity [28,29].
Intracellular G6P levels were expressed as nmols/mg protein.
Western blot analysis
Aliquots from mitochondria-enriched and cytosolic cellular
fractions were normalized for protein content (25 mg protein/lane)
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nitrocellulose membranes. Hexokinase levels were determined
from total, unfractionated neuronal extracts separated on 12%
SDS-PAGE gels and blotted onto nitrocellulose membranes.
Membranes were incubated with anti-HK1 (1:500 dilution), anti-
cytochrome c oxidase (1:500 dilution, used as a loading control for
mitochondria-enriched fractions) and anti-cyclophilin B (1:4,000
dilution, used as a loading control for cytosolic fractions)
antibodies. Protein bands were visualized by staining with
horseradish peroxidase-labeled secondary antibody (1:100,000)
followed by enhanced chemiluminescence detection.
Results
Ab induces inhibition of neuronal mitochondrial-bound
hexokinase I (m-HKI) by interference with subcellular
localization
Brain HKI is mainly (,70–90%) associated with the mitochon-
drial membrane and release of HK from mitochondria causes a
significant decrease in enzyme activity [5,6]. To test whether Ab
interferes with the subcellular localization of neuronal m-HKI, we
measured HKI protein levels in mitochondrial fractions by
western immunobloting. HKI levels were reduced by ,40% in
the mitochondrial fraction from Ab-treated neurons (Fig. 1A). In
agreement with the decrease in levels of mitochondrial-bound
hexokinase, the activity determined in the mitochondria-enriched
fraction from Ab-treated neurons was significantly (,40%) lower
than the activity measured in mitochondria from vehicle-treated
neurons (Fig. 1B). We also found that 5 mMA b induced , 20%
decrease in total neuronal HKI activity (Fig. 1C). These results
show that Ab interferes with the subcellular localization of HK,
causes the release of HKI from mitochondria. In order to
investigate the effect of Ab on m-HKI activity, we have next
proceeded checking whether Ab directly inhibits HK. m-HKI
activity was then measured in mitochondria isolated from adult rat
brains incubated with Ab.A b did not directly inhibit hexokinase,
even at a high concentration (20 mM) (Fig. 1D). This suggests that
Ab only has an impact on HKI when the enzyme is associated
with the mitochondrial membrane in the neuronal cellular
context.
Figure 1. Ab inhibits HKI by triggering the release of m-HKI from mitochondria. Panel A: Western immunoblot analysis of HKI levels in
mitochondrial fractions from cultured cortical neurons exposed to 5 mMA b for 24 hours. Cytochrome c oxidase was used as a loading control. Bars
correspond to means 6 SE from at least three independent experiments carried out in duplicate. Panel B: HK activity as measured in mitochondrial
enriched fractions from cultured cortical neurons exposed to 5 mMA b for 24 hours. Bars correspond to means 6 S.D. from three independent
experiments carried out in duplicate. Panel C: HK1 activity as measured in cortical neurons exposed to 5 mMA b for 24 hours. Bars represent the
means 6 SD from three independent experiments carried out in duplicate. (*) indicates a statistically significant (p,0.005) difference relative to
control (vehicle-treated) cultures. Panel D: HK activity in mitochondria isolated from adult rat brains was measured in the absence or in the presence
of Ab (5 mMo r2 0mM; 1 hour). Values represent means 6 SD of the activity measured in two independent experiments carried out in triplicate.
doi:10.1371/journal.pone.0015230.g001
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bound HKI and impair neuronal energy metabolism
Because soluble Ab oligomers (also known as ADDLs) have
recently been recognized as the proximal neurotoxins in AD [17–
19], we next investigated whether a defined preparation of soluble
Ab oligomers would instigate HKI release from mitochondria.
Indeed, HKI levels were 40% reduced in the mitochondrial
fraction from neurons treated with 500 nM ADDLs for 24 hours
(Fig. 2A). Results demonstrate that Ab oligomers instigate
neuronal HKI release from mitochondria.
The impact of Ab oligomers on mitochondrial redox activity
was further evaluated using the MTT reduction assay in our
model of mature hippocampal neuronal cultures. Neurons were
exposed to ADDLs or monomers for 24, 48 or 96 h with ADDLs
(Fig. 2B). After 24 h, no significant toxicity was observed in the
presence of ADDLs or monomers, used as a control. Only at
longer incubation times (48 and 96 h), ADDLs caused a
progressive decrease in MTT reduction, while Ab monomers
had no effect (Fig. 2B).
ATP is essential for the excitability and survival of neurons, as
well as for protein phosphorylation reactions that mediate synaptic
signaling and associated changes in neuronal structure and
function [28]. Because the results presented above have indicated
mitochondrial impairment in ADDL-treated neurons, we next
measured ATP levels in cortical neurons treated with 500 nM
ADDLs for 12 hours, well before an effect on mitochondrial redox
activity could be observed (Fig. 2B). Results show a marked
decrease in ATP levels in ADDL-treated neurons (Fig. 2C),
substantiating the neuronal energy metabolism impairment caused
by Ab oligomers.
Hexokinase activity blocks Ab-induced generation of
reactive oxygen species (ROS)
We have previously shown that impaired m-HKI activity results
in increased ROS levels in neurons [8]. In order to investigate the
possible role of m-HKI in neuronal oxidative stress induced by Ab,
intracellular ROS levels were evaluated in cortical neurons treated
with 5 mMA b or vehicle for 6 hours, in the absence or presence of
2-deoxyglucose (2DOG), an alternative substrate of hexokinase.
Phosphorylation of 2-DOG by hexokinase gives rise to the
formation of 2-deoxyglucose 6-phosphate (2-DOG6P), which does
not inhibit hexokinase activity in the same range as G6P and
consequently preserves HK1 activity [4,8,29]. In agreement with
previous findings [14], Ab induced a significant increase in
neuronal ROS levels (Fig. 3B, D). Interestingly, addition of
30 mM 2-DOG to the culture medium completely blocked the
excessive intracellular ROS production induced by Ab (Fig. 3C,
D). Such results reveal an important antioxidant role of HKI in the
prevention of Ab-induced oxidative stress.
When neurons were treated with 5 mM FCCP (an uncoupler of
oxidative phosphorylation that reduces mitochondrial membrane
potential) in the presence or absence of Ab, ROS levels became
lower than those observed in control cultures (Fig. 3D), indicating
that ROS formation in our experiments originates in mitochon-
dria. We next measured intracellular G6P levels in cortical
neurons exposed to Ab, as G6P is a potent inhibitor of m-HKI at
physiological concentrations and causes its release from brain
mitochondria [29]. We found that treatment with 2-DOG, both in
the absence and in the presence of Ab greatly decreased neuronal
G6P levels (Fig. 3E). Results indicate that the protective effects of
2-DOG may involve a decrease in intracellular G6P levels, thus
counteracting the inhibition of HKI by Ab and leading to
decreased mitochondrial ROS production and death via enhanced
ADP recycling.
DOG blocks Ab-induced neuronal death
Finally, we investigated whether 2-DOG protects neurons
against Ab-induced neurodegeneration. Cortical neurons were
treated for 48 hours with Ab in the absence or presence of 2-DOG
and neuronal viability was determined using the Live/Dead assay.
A marked neurodegeneration was observed in cultures exposed to
20 mMA b1-42 for 48 hours (Fig. 4). Remarkably, 2-DOG led to
significant blockade of Ab-induced neuronal death (Fig. 4). 2-
Figure 2. Effects of Ab oligomers on neuronal m-HKI and ATP levels. Panel A: Ab oligomers triggers the release of m-HKI from mitochondria.
Western immunoblot analysis of HKI levels in mitochondrial fractions from cultured cortical neurons exposed to 500 nM Ab oligomers (ADDLs) (D) for
24 hours. Cytochrome c oxidase was used as a loading control. Bars correspond to means 6 SE from at least three independent experiments carried
out in duplicate. Panel B: Time-dependent toxicity of ADDLs (white bars) or Ab monomers (gray bars) to mature hippocampal neurons measured
using the MTT reduction assay. Values represent the means 6 SD of the relative absorbance measured using 6 wells for each experimental condition
for three independent experiments. (*) indicates a statistically significant (p,0.005) difference relative to control cultures. Panel C: Ab oligomers
decrease ATP levels in mature cortical neurons. Cultures were exposed to vehicle or 500 nM ADDLs for 12 hours. Values represent means 6 SD of the
relative levels measured in five independent experiments.
doi:10.1371/journal.pone.0015230.g002
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during 48 hours (Fig. 4D). Finally, we investigated if 2-DOG could
interfere with HK1 levels. Increased total levels of HKI were
found in cortical neurons treated with 30 mM 2-DOG (Fig. 4E),
suggesting that the neuroprotective effect afforded by 2-DOG may
also involve up-regulation of HKI levels.
Discussion
In the present work we show that Ab, the neurotoxin thought to
be responsible for neuronal deterioration in Alzheimer’s disease
(AD), causes the release of hexokinase from mitochondria and a
parallel inhibition of enzyme activity. Mitochondrial-bound
hexokinase (m-HKI) regulates important cellular processes in
neurons, including ATP synthesis, maintenance of glutathione
levels and neurite outgrowth [6,7,30]. Importantly, we have
previously shown that m-HKI participates in a local ADP
recycling mechanism that is directly involved in the regulation of
mitochondrial oxidative homeostasis, preventing neurons from
oxidative damage [8]. Oxidative stress is an important facet of AD
[12–14]. We have now established that the impact of Ab on
neuronal hexokinase triggers mitochondrial oxidative stress and
neuronal death. Importantly, the glucose analogue, 2-DOG,
prevented Ab-induced inactivation of m-HKI, and blocked
excessive mitochondrial ROS formation and neuronal death.
Ab-induced cellular redistribution and inactivation of m-HKI may
play central roles in oxidative stress and neurodegeneration in AD.
While monomeric Ab is not neurotoxic, the peptide exhibits a
marked toxic gain-of-function upon self-association. Fibrillar forms
of Ab found in amyloid plaques are toxic to neurons [21,31] and
were until recently considered being mainly responsible for
neuronal damage in AD. More recently, however, new evidence
has emerged demonstrating that Ab oligomers, aggregates that are
soluble and much smaller than fibrils, are potent neurotoxins in
AD pathogenesis [17,18], causing neuronal dysfunction at much
lower concentrations than fibrillar aggregates. Ab oligomers
accumulate in the brains of AD patients [32,33] and have been
linked to major AD pathology hallmarks, including neuronal tau
hyperphosphorylation [24], oxidative stress [14,15] and synapse
deterioration [25]. Interestingly, oligomers from a non-disease
related protein have been shown to mimic Ab-induced tau
hyperphosphorylation and neurodegeneration [26]. Ab oligomers
further inhibit long-term potentiation (LTP) [34,35]. Our results
reveal a novel deleterious neuronal impact of Ab oligomers,
causing m-HKI release from mitochondria (Fig. 2).
We also found that Ab oligomers cause a marked reduction in
neuronal ATP levels (Fig. 2). Impairment of brain energy
metabolism is another major facet in AD that has been revealed
by in vivo studies of glucose utilization [12,36]. Brain energy
metabolism is also altered in transgenic mouse models of AD that
Figure 3. 2-DOG blocks Ab-induced neuronal ROS formation. Representative DCF fluorescence images from control (vehicle-treated) cultures
(Panel A), cultures exposed to 5 mMA b for 6 hours (Panel B) or cultures exposed to 5 mMA b+30 mM 2-DOG for 6 hours (Panel C). When present, 2-
DOG was added 10 minutes before Ab. In order to allow direct comparison between ROS levels, identical conditions and exposure times for image
acquisition were employed for all experimental conditions. Panel D: Quantitative analysis of DCF fluorescence from five independent experiments
(, 1,500 cells analyzed per experimental condition in each experiment) using ImageJ software (NIH Windows version). (*) indicates a statistically
significant (p,0.005) difference relative to control cultures. (**) and (***) indicates a statistically significant (p,0.005) difference relative to Ab-treated
cultures. Scale bar corresponds to 100 mm. Panel E: 2-DOG decreases neuronal G6P levels in neurons exposed to Ab. Glucose-6P levels were measured
in control cortical neurons or neurons exposed to 5 mMA b+30 mM 2-DOG or 30 mM 2-DOG. Values represent means 6 SD from three experiments
(carried out in duplicate) using independent neuronal cultures. (*) indicates a statistically significant (p,0.001) difference relative to control cultures.
doi:10.1371/journal.pone.0015230.g003
Ab Inhibits Neuronal Hexokinase 1
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15230present Ab deposition and elevated levels of Ab oligomers [37,38].
The brain relies almost exclusively on glucose as its source of
energy, using approximately 25% of circulating sugar. Normal
glucose levels have been shown to protect brain cells from
apoptotic events [39], demonstrating that a fine regulation of
metabolism is crucial to cellular survival under stress conditions.
Glial cells are believed to take up a significant fraction of glucose
from the blood and provide neurons with lactate and glucose-
derived energy substrates to sustain their activity [40,41].
Nonetheless, neurons also rely directly on glucose provided via
the extracellular space by the cerebral circulation. Conversion of
glucose to G6P and oxidative phosphorylation take place both in
neurons and glial cells and generate the ATP required to drive
many cellular processes, including the excitability and survival of
neurons and intracellular signaling pathways related to neuronal
plasticity [28]. Our finding that Ab oligomers decrease neuronal
ATP levels indicates that they are linked to the impairment of
energy metabolism in neurons. This might, at least in part, explain
the deficits in glucose utilization in AD brains, a condition believed
to result in synaptic dysfunction, neuronal degeneration and
cognitive impairment.
Interestingly, Ab did not inhibit hexokinase activity measured in
an isolated mitochondria preparation (Fig. 1D). Rather, inhibition
of m-HKI was observed when cortical neurons in culture were
treated with Ab (Fig. 1B). This suggests that Ab-induced
inactivation of m-HKI only occurs when the enzyme is associated
with the mitochondrial membrane in the neuronal cellular
context. Further studies will be required to investigate whether
Ab directly interacts with m-HKI in neurons. An elegant study
demonstrated that Ab interacts with alcohol dehydrogenase in the
mitochondria of AD patients and transgenic mice [42]. In
addition, nicastrin, presenilin, APH-1 and PEN-2 form active
gamma-secretase complexes in mitochondria [43], suggesting that
Ab can be physiologically formed in mitochondria.
Another possibility is that Ab interaction with specific
membrane receptors causes deregulation of intracellular signaling
cascades that result in m-HKI inhibition. We have shown that Ab
oligomers induce abnormal Ca
2+ influx and neuronal oxidative
stress through aberrant activation of N-methyl-D-aspartate
(NMDA) receptors [14]. Several lines of evidence suggest that
Ab interferes with Wnt/b-catenin signaling [44,45], causing GSK-
3b activation, a kinase abnormally active in AD and involved in
tau phosphorylation [46,24]. GSK-3b phosphorylates VDAC,
causing HKII release from mitochondria in HeLa cells [47]. Akt
activation is required to maintain hexokinase attachment to
mitochondria [30]. Growth factors known to induce Akt
Figure 4. 2-DOG blocks Ab-induced neurodegeneration. Neuronal cortical cultures were maintained in the absence or in the presence of Ab
for 48 hours and cell viability was determined using the Live/Dead assay as described in ‘‘Materials and Methods’’. Live cells are identified by green
calcein fluorescence and dead cells are identified by red ethidium bromide fluorescence. Representative images from control (vehicle-treated)
cultures (Panel A), cultures exposed to 20 mMA b (Panel B) or cultures treated with 20 mMA b+30 mM 2-DOG (Panel C). Panel D: Quantitative analysis
of neuronal viability was carried out using Image J (described in ‘‘Methods’’). A total of 3,000–4,000 cells were analyzed in each experimental
condition. Bars show means 6 SD from four different experiments (carried out in triplicate). (*) and (**) indicates a statistically significant (p,0.005 or
p,0.01, respectively) difference relative to control cultures. Scale bar corresponds to 100 mm. Panel E: Effects of 2-DOG on neuronal HKI levels.
Western immunoblot analysis of total HKI levels from cultured cortical neurons exposed to 30 mM 2-DOG for 48 hours. Cyclophilin B was used as a
loading control. Bars correspond to means 6 SD from four independent experiments.
doi:10.1371/journal.pone.0015230.g004
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HK association to VDAC, protecting against Ab. Insulin in fact
has recently been shown to protect synapses against Ab oligomers
[25].
Neuronal oxidative stress is a hallmark of AD pathology.
Neurons in culture exposed to Ab present increased markers of
oxidative stress [14,48,49]. It is well established that mitochondrial
ROS formation triggers early events in apoptosis, including
mitochondrial swelling, cytochrome c release and caspase
activation [12]. During aging, neurons are subject to increased
oxidative stress and impaired energy metabolism, leading to
dysfunction of proteins responsible for maintaining proper
membrane excitability and subcellular Ca
2+ dynamics [28].
Oxidative stress destabilizes Ca
2+ homeostasis and renders
neurons vulnerable to excitotoxicity and apoptosis [50]. Mito-
chondria preserve neuronal Ca
2+ homeostasis by generating the
ATP required to pump Ca
2+ out of the cytoplasm and by buffering
cytosolic Ca
2+ loads needed during normal synaptic activity [51].
Ab-induced mitochondrial dysfunction and oxidative stress (Fig. 3)
may thus be of central importance to disrupt neuronal Ca
2+
homeostasis.
Excessive ROS formation due to hyperpolarization of the
mitochondrial membrane has also been shown to result from
hyperglycemic neuronal injury, a condition in which m-HKI is
inhibited by accumulation of G6P [8,29,52]. It is possible,
therefore, that the decrease in intraneuronal G6P levels in the
presence of 2-DOG (Fig. 3E) relieves the inhibition of m-HKI,
sustaining a steady-state ADP recycling that sets down the
mitochondrial membrane potential to lower levels and, conse-
quently, protects neurons from Ab-induced oxidative stress. Our
finding that 2-DOG completely blocked Ab-induced ROS
formation and neuronal death (Figs. 3 and 4) further indicates
that preserving neuronal m-HKI activity by preventing its release
from mitochondria plays a key role in neuronal survival. Blocking
the impact of Ab on m-HKI may provide a novel therapeutic
approach to prevent oxidative stress and neurodegeneration in
AD.
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